Found: 11
Select item for more details and to access through your institution.
Genetic Linkage of FcγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy.
- Published in:
- Clinical Cancer Update, 2007, v. 1, n. 1, p. 74, doi. 10.3816/CCU.2007.n.012
- By:
- Publication type:
- Article
Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 4, p. 286
- By:
- Publication type:
- Article
Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 139, n. 1, p. 193, doi. 10.1007/s10549-012-2375-z
- By:
- Publication type:
- Article
Novel p53 splice site mutations in three families with Li-Fraumeni syndrome.
- Published in:
- Oncogene, 2000, v. 19, n. 37, p. 4230, doi. 10.1038/sj.onc.1203758
- By:
- Publication type:
- Article
p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome.
- Published in:
- Oncogene, 1999, v. 18, n. 27, p. 3970, doi. 10.1038/sj.onc.1202783
- By:
- Publication type:
- Article
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer.
- Published in:
- Frontiers in Oncology, 2017, p. 1, doi. 10.3389/fonc.2017.00191
- By:
- Publication type:
- Article
Aberrant RHAMM (receptor for hyaluronan-mediated motility) splicing in MM is associated with upregulation of PTBP1/2 (polypyrimidine tract binding protein 1/2): therapeutic implications.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e123, doi. 10.1016/j.clml.2019.09.204
- By:
- Publication type:
- Article
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00791-0
- By:
- Publication type:
- Article
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 2, p. 223, doi. 10.1111/j.1365-2141.2011.08726.x
- By:
- Publication type:
- Article
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 1, p. 59, doi. 10.1111/j.1365-2141.2009.07592.x
- By:
- Publication type:
- Article
Common polymorphism in p53 intron 2, IVS2+38G>C.
- Published in:
- Human Mutation, 2000, v. 16, n. 2, p. 181, doi. 10.1002/1098-1004(200008)16:2<181::AID-HUMU23>3.0.CO;2-O
- By:
- Publication type:
- Article